The 2026 Spring to Life conference, hosted by New York Oncology Hematology (NYOH), will spotlight the evolving landscape of plasma cell disorders, with a focus on translating emerging evidence into clinical practice. Designed for a diverse, interprofessional healthcare audience, this year s program will explore the continuum from premalignant conditions (MGUS, MGRS, smoldering myeloma) to advanced disease states, while addressing both malignant and benign hematology.

Participants will gain insight into current and novel therapeutic approaches, including CAR-T therapy, bispecific antibodies, and next-generation sequencing (NGS) for minimal residual disease (MRD) assessment. The conference will also feature rare plasma cell disorders such as AL amyloidosis, Castleman disease, and POEMS syndrome, as well as targeted discussions on underserved conditions like sickle cell disease. A keynote session will explore the future of myeloma care, including the potential for functional cures and treatment-free intervals.

Through evidence-based updates, case discussions, and interdisciplinary dialogue, this event will foster collaboration to advance patient outcomes across hematologic care settings. The 2026 Spring to Life conference, hosted by New York Oncology Hematology (NYOH), will spotlight the evolving landscape of plasma cell disorders, with a focus on translating emerging evidence into clinical practice. Designed for a diverse, interprofessional healthcare audience, this year s program will explore the continuum from premalignant conditions (MGUS, MGRS, smoldering myeloma) to advanced disease states, while addressing both malignant and benign hematology. Participants will gain insight into current and novel therapeutic approaches, including CAR-T therapy, bispecific antibodies, and next-generation sequencing (NGS) for minimal residual disease (MRD) assessment. The conference will also feature rare plasma cell disorders such as AL amyloidosis, Castleman disease, and POEMS syndrome, as well as targeted discussions on underserved conditions like sickle cell disease.

A keynote session will explore the future of myeloma care, including the potential for functional cures and treatment-free intervals. Through evidence-based updates, case discussions, and interdisciplinary dialogue, this event will foster collaboration to advance patient outcomes across hematologic care settings.

Thank you for attending this conference.  Your feedback is valuable to us.

To receive your Certificate of Attendance, complete and submit the Evaluation Form. Once this form is submitted your certificate will be available for download.

Registered attendees can earn a maximum of 9.25 CME/ABIM MOC/CE credits. You will be able to select the amount of credits being claimed.

Physicians: If you would like to earn MOC credit please complete the Post-Test prior to submitting the evaluation. Once submitted, you will not be able to go back to complete the Post-Test. In order for MEC to report your MOC credit, your ABIM Diplomate ID number and date of birth (mm/dd/yyyy) MUST be included in your MyMedflix user profile. A completed evaluation and passing score of 70% on the post-test is required. You will have (3) attempts to pass the test.

Pharmacists: NABP e-profile number and date of birth (mm/dd/yyyy). Your CE credits will be electronically submitted to CPE Monitor® within 60 days upon successful completion of the activity.

For questions regarding credit for this activity, please contact MEC at info@meccinc.com. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.